• See how Merck is demonstrating durable responses with ATR inhibition in ATRX-mutant gliomas, a poor-prognosis subtype

• Outlining the synthetic lethality rationale linking ATRX loss, alternative lengthening of telomeres (ALT), and ATR dependency

• Presenting ongoing studies confirming early signals and discussing opportunities to integrate biomarker-driven patient selection into glioma trial design